OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Thrombosis and Thrombolysis is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database	49
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection	45
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity	45
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery	34
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia	34
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team	29
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry	28
Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment	28
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians	24
Management of bone marrow biopsy related bleeding risks: a retrospective observational study	24
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors	24
Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status	23
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate	22
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia	21
Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic	20
Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer	19
Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-dimer testing followed by CTPA	18
Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals	17
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series	17
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy	17
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone	17
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients	16
Potent platelet inhibition with peri-procedural tirofiban may attenuate progression of atherosclerosis in patients with acute coronary syndromes	16
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding	16
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy	16

Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review	15
Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection	14
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes	14
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison	14
Evaluation of coagulation status using clot waveform analysis in general ward patients with COVID-19	14
Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality	14
Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies	13
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome	13
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized tri	13
Effectiveness and safety of the direct oral anticoagulants in non-triple positive antiphospholipid syndrome without prior arterial thromboembolism	13
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum	13
Thrombosis in VEXAS syndrome	13
Venous and arterial thromboembolic disease in COVID-19	12
Popliteal cysts are not a risk factor for lower extremity deep vein thrombosis	12
Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes	12
Forensic autopsy-confirmed thrombosis-related deaths: the danger in the bones	12
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis	12
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy	11
Thrombotic superior vena cava syndrome: a national emergency department database study	11
The clot thickens—enhanced integration of stroke and thrombosis training	11
Metformin therapy in COVID-19: inhibition of NETosis	11
Endothelial progenitor cells overexpressing platelet derived growth factor-D facilitate deep vein thrombosis resolution	11
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study	11
Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction	11
Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall	10
Atypical late diagnosis of Noonan syndrome revealed by bleedings due to platelet dysfunction	10
Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event	10
Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation	10
Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid	10
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature	9
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients	9
Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial ınfarction (STEMI) in Turkey: results from TURSER study (TURKISH St-segment elevation myocardial ınfarction registry)	9
Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves	9
Vitamin D levels and C-reactive protein/albumin ratio in pregnant women with cerebral venous sinus thrombosis	9
Management of tandem occlusions in patients who receive rtPA	9
Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-19	9
Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	9
U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients	9
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia	9
A comprehensive review of vascular complications in COVID-19	9
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States	8
Time to consider neuroinflammation as a booster effect of cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia?	8
Subclinical leaflet thrombosis after transcatheter aortic valve replacement and anticoagulant treatment: lights and shadows	8
Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes	8
Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation	8
Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti-coagulants and beyond	8
Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation	8
Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism	8
SARS-CoV-2 antibody research in patients with unprovoked pulmonary embolism in COVID-19 pandemic period	8
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors	8

Thromboembolic events following mRNA vaccines for COVID 19: a case series	8
Incremental cost of venous thromboembolism in trauma patients with contraindications to prophylactic anticoagulation: a prospective economic study	7
Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis	7
Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19	7
Juvenile patients with the homozygous MTHFR C677T genotype develop ischemic stroke 5 years earlier than wild type	7
The safety and efficacy of systemic versus catheter-based therapies: application of a prognostic model by a pulmonary embolism response team	7
Thrombectomy for ischemic stroke with large vessel occlusion and concomitant subarachnoid hemorrhage	7
Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series	7
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome	7
Inhibitory effects of amniotic fluid on the activated protein C anticoagulation system in maternal plasma	7
Activated clotting time in inpatient diagnostic and interventional settings	7
Correction to: Cardiomyocyte microvesicles: proinflammatory mediators after myocardial ischemia?	7
Barriers and motivators to national board certification as a certified anticoagulation care provider	7
Recurrent hematuria and painful necrotic purpura induced by acquired Protein S deficiency associated with monoclonal immunoglobulin	7
A survey of internists’ recommendations for aspirin in older adults and barriers to evidence-based use	7
Intravenous thrombolysis and endovascular thrombectomy for acute ischaemic stroke in patients with Moyamoya disease - a systematic review and meta-summary of case reports	7
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials	7
Utilization trends and outcomes of catheter-directed thrombolysis for pulmonary embolism in the US by race/ethnicity	6
Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells	6
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism	6
Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012)	6
Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes	6
Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation pati	6
Immature platelets in patients with Covid-19: association with disease severity	6
Contemporary use of ventilation-perfusion imaging for pulmonary embolism diagnosis	6
REPLY to “Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	6
One-year clinical outcome of patients with left ventricular thrombus after acute myocardial infarction discharged on triple or dual antithrombotic therapy	5
Primary pulmonary artery sarcoma versus pulmonary thromboembolism: a multimodal imaging comparison	5
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS	5
Evaluation of heparin infusion rates in patients with intravenous drug misuse	5
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study—Reply to comment from Muzaffar et al.	5
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study	5
Correction to: Efficacy of interatrial shunt devices: an opening window to acute pulmonary hypertensive crisis and chronic pulmonary arterial hypertension	5
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study	5
Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study	5
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19	5
Association of acidosis with coagulopathy and transfusion requirements in liver transplantation	5
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists	5
The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature	5
Impact of thrombus burden on long-term clinical outcomes in patients with either anterior or non-anterior ST-segment elevation myocardial infarction	5
International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests	5
Factor Xa inhibitors: critical considerations for clinical development and testing	5
Increased risk of venous thromboembolism among patients with familial Mediterranean fever	5
Answer to “REPLY to Association between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	5
Acute coronary syndrome in patients with hemophilia: a delicate balancing act	5
Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis	5
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry	5
Thrombocytosis and neutrophilia associated with oxygenator failure and protamine reaction after cardiopulmonary bypass: a case report and literature review	5
Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective	5
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study	5
Venous thromboembolism in non-COVID-19 population during the pandemic: a nationwide multicenter retrospective survey	5